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ABSTRACT 24 
HSV-2 increases HIV-1 acquisition and transmission via an unclear mechanism. HSV-2 entry 25 
receptor herpesvirus entry mediator (HVEM) is highly expressed on HIV-1 target cells CD4+ T 26 
cells and may be incorporated into HIV-1 virions, while HSV-2 glycoproteins can be present on 27 
infected cell surface. Since HVEM-gD interaction together with gB/gH/gL is essential for HSV-28 
2 entry, HVEM-bearing HIV-1 (HIV-1/HVEM) may enter HSV-2-infected cells through such 29 
interactions. To test this hypothesis, we first confirmed the presence of HVEM on HIV-1 virions 30 
and glycoproteins on HSV-2-infected cell surface. Additional studies showed that HIV-1/HVEM 31 
bound to HSV-2-infected cell surface in an HSV-2 infection-time-dependent manner via HVEM-32 
gD interaction. HIV-1/HVEM entry of HSV-2-infected cells was dependent on HVEM-gD 33 
interaction and the presence of gB/gH/gL, and was inhibited by azidothymidine (AZT). 34 
Furthermore, peripheral blood mononuclear cells (PBMCs)-derived HIV-1 infected HSV-2-35 
infected primary foreskin epithelial cells and the infection was inhibited by anti-HVEM/gD 36 
antibodies. Together, our results indicate that HIV-1 produced from CD4+ T cells bears HSV-2 37 
receptor HVEM and can bind to and infect HSV-2-infected epithelial cells depending on HVEM-38 
gD interaction and the presence of gB/gH/gL. Our findings provide a potential new mechanism 39 
underlying HSV-2 infection-enhanced HIV-1 mucosal transmission and may shed light on HIV-40 
1 prevention.   41 
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INTRODUCTION 42 
Human immunodeficiency virus type 1 (HIV-1) infection is usually accompanied by co-43 
infections of other pathogens including herpes simplex virus type 2 (HSV-2) [1]. Like HIV-1, 44 
HSV-2 is also sexually transmitted, but targets different cell subsets. HSV-2 predominantly 45 
infects epithelial cells, causing mucosal ulceration, and can also infect immunocytes and neurons 46 
[2-4]. Both epidemiological and clinical data have suggested that HSV-2 infection enhances 47 
HIV-1 acquisition and transmission up to three folds, but the underlying mechanisms remain to 48 
be defined [5-10]. HSV-2 is around 11.3 % (417 million) positive in the general population globe 49 
wide with an annual new infection rate of 0.5 % (19.2 million) [11]. Moreover, data from World 50 
Health Organization (WHO) indicate that 60-90 % of HIV-1-infected individuals are co-infected 51 
with HSV-2 [12]. Consequently, understanding the mechanisms underlying HSV-2-enhanced 52 
HIV-1 acquisition and transmission is crucial for HIV-1 prevention and treatment. 53 
 54 
To date, several potential mechanisms from different perspectives have been proposed, which 55 
can be generally divided into two categories. One is that HSV-2 infection would generate 56 
ulceration and consequently disrupt the integrity of the mucosal barrier and allow HIV-1 57 
infection of target cells underneath [10, 13-15]. The other is that inflammatory responses at the 58 
site of HSV-2 infection could cause enrichment of immunocytes including HIV-1 target cells at 59 
these sites [9, 16, 17]. However, all these potentials mechanisms have yet to be confirmed. In 60 
addition, the above presumptions all focus on the potential changes of topical microenvironment 61 
following HSV-2 infection, but little is known concerning the roles played by HIV-1 virion 62 
itself.  63 
 64 
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CD4-independent HIV-1 infection of non-target cells has been described in HIV-1 co-infection 65 
with other viruses. For instance, under the condition of HIV-1 and herpes simplex virus 1 (HSV-66 
1) co-infection, HIV-1 infection of CD4- keratinocytes was observed [18]. HIV-1 infection of a 67 
variety of CD4- cell subsets including CD8+ T cells, B cells, epithelial cells and even skeletal 68 
muscle cells was reported in the context of HIV-1 and human T-lymphotropic virus 1 (HTLV-1) 69 
co-infection [19]. HIV-1 infection of female genital epithelial cells was also described when co-70 
infected with xenotropic murine leukemia virus-related virus (XMRV) [20]. We hypothesized 71 
that, under the circumstances of HIV-1 and HSV-2 infection, HSV-2-induced changes on 72 
epithelial cells may be beneficial for HIV-1 to establish infection.  73 
 74 
As an enveloped virus, HIV-1 obtains its membrane from host cells during viral budding, which 75 
consequently contains host cell components [21]. Herpesvirus entry mediator (HVEM), an HSV-76 
2 entry receptor, is highly expressed on HIV-1 target cells CD4+ T cells [22]. Theoretically, 77 
HVEM is likely present on the surface of HIV-1 virion. HSV-2 is also an enveloped virus. 78 
Although its viral packaging usually takes place in the Golgi apparatus, HSV-2 glycoproteins 79 
may be partially present on the host cell surface owing to the overexpression of viral proteins and 80 
the trafficking of cell membrane system [23]. Since HSV-2 glycoprotein D interaction with its 81 
receptor HVEM together with the presence of three viral glycoproteins gB, gH and gL 82 
(designated as HVEM-gB/gD/gH/gL) are essential for successful viral entry, HVEM-bearing 83 
HIV-1 (designated as HIV-1/HVEM hereafter) may be able to enter HSV-2-infected cells 84 
through such interactions [24, 25].  In the current study, using both cell lines and primary 85 
foreskin epithelial cells as models, we tested whether HIV-1/HVEM could infect HSV-2-infected 86 
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epithelial cells and whether this type of infection is HVEM-gD interaction- and gB/gH/gL -87 
dependent.   88 
 89 
RESULTS 90 
HVEM is present on HIV-1 virions. 91 
To test our hypothesis that HVEM-gD interaction together with gB/gH/gL may mediate HIV-1 92 
entry of non-target epithelial cells, we first examined the presence of HVEM on HIV-1 virions. 93 
We conducted experiments to address whether HVEM is expressed on HIV-1 target CD4+ T 94 
cells and whether it can be incorporated into HIV-1 virions. Freshly isolated peripheral blood 95 
mononuclear cells (PBMCs) from different donors were assessed for the cell surface expression 96 
of CD4 and HVEM, respectively. Our results showed that a near 100 % HVEM expression was 97 
observed on PBMCs regardless of donor origins, and not surprisingly almost 100 % CD4+ T cells 98 
express HVEM (Fig. 1a) [22].  99 
 100 
We next determined whether HVEM is incorporated into the viral membrane during progeny 101 
viral budding. HIV-1 from various sources was concentrated by ultracentrifugation, lysed and the 102 
presence of HVEM was determined by Western blot. As shown in Figure 1b, HVEM expression 103 
was detected from HIV-1 pellets generated from both PBMCs and HVEM-expressing 293T 104 
(293T-HVEM) cells. In contrast, no HVEM was detected from virions generated from 293T 105 
cells. Pelleted HIV-1 supernatants are usually contaminated with microvesicles. Our data showed 106 
that microvesicles, as indicated by acetylcholinesterase (AChE), were present in pelleted HIV-1 107 
samples. To confirm that HVEM detected in the pellets was associated with HIV-1 virions rather 108 
than contaminant microvesicles, we pelleted cell culture supernatants from mock-treated 293T, 109 
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293T-HVEM and PBMC cells, respectively, and assessed the presence of HVEM. Our data 110 
showed that no HVEM was detected in the pellets of mock-treated cell culture supernatants, 111 
indicating that HVEM is associated with HIV-1 but not contaminant microvesicles (Fig. 1b). To 112 
further confirm these results, pelleted virus stocks were purified by 6–18% Optiprep™ density 113 
gradient and HVEM presence in the purified viruses were determined. As shown in Figure 1c, 114 
HVEM was successfully detected in purified HIV-1 derived from 293T-HVEM and PBMCs. 115 
These data together indicate that HVEM is highly expressed on CD4+ T cells and can be 116 
incorporated into HIV-1 virions during virus budding.  117 
 118 
HIV-1/HVEM binds to HSV-2-infected cell surface via HVEM-gD interaction. 119 
Cell surface presentation of viral glycoproteins and the viability of HSV-2-infected cells are two 120 
important factors determining the entry of HIV-1/HVEM in HSV-2-positive cells. Our data 121 
showed that HSV-2 gB and gD on cell surfaces of infected ME-180 and HeLa cells increased in 122 
a time dependent manner and peaked around 24 h (Fig.S1). Cell viability assay showed that, 123 
although HSV-2 infection disrupted cell morphology of both ME-180 and HeLa cells in an 124 
infection dose dependent manner, the majority of infected cells remained viable 30 h after 125 
infection as evidenced by 7-aminoactinomycin D (7-AAD) staining (Fig. S2).  126 
 127 
We subsequently investigated whether HIV-1/HVEM could bind to HSV-2 infected epithelial 128 
cells. Two cervical epithelial cell lines HeLa and ME-180 were adopted in the assay. As shown 129 
in Fig.2a, binding of HIV-1/HVEM to HSV-2-infected cells was significantly increased in an 130 
HSV-2 infection time dependent manner, whereas HIV-1/BaL did not show such a binding 131 
pattern. Similar binding profiles of HIV-1/HVEM were observed in both HeLa and ME-180 cell 132 
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lines following HSV-2 infection, although higher level of binding was on ME-180 than on HeLa 133 
cells. 134 
 135 
HVEM serves as a receptor for gD during HSV-2 entry. We further determined whether the 136 
binding of HIV-1/HVEM to HSV-2 infected cell surface was dependent on HVEM and HSV-2 137 
glycoproteins. HSV-2 glycoproteins gB, gD, gH and gL alone or in combinations was expressed 138 
in HeLa and ME-180 cells, followed by the assessment of HIV-1/HVEM binding. Our results 139 
showed that HIV-1/HVEM bound to cells transfected with HSV-2 gB/gD/gH/gL, and such 140 
binding appeared to be gD-dependent (Fig. 2b). These data suggest that binding of HIV-141 
1/HVEM to HSV-2-infected cell surface is dependent on the interaction between HVEM and gD. 142 
 143 
HIV-1/HVEM enters HSV-2-infected cells in an HVEM-gB/gD/gH/gL dependent manner. 144 
We next asked whether the binding of HIV-1/HVEM to HSV-2 infected epithelial cells could 145 
lead to viral infection. HeLa or ME-180 cells were infected with HSV-2 followed by co-146 
cultivation with HVEM-bearing replication-competent HIV-1BaL (HIV-1BaL/HVEM) in the 147 
presence or absence of HIV-1 reverse transcriptase inhibitor (azidothymidine, AZT). 148 
Quantification of in-cell HIV-1 p24 showed that p24 was only detected in cells pre-infected with 149 
HSV-2 but not in those without HSV-2 infection. Moreover, the addition of AZT almost 150 
completely inhibited p24 production, indicating that a productive HIV-1 infection took place in 151 
HSV-2 infected epithelial cells (Fig.3a).  152 
 153 
By assessing HIV-1/HVEM entry of HSV-2 gB/gD/gH/gL transfected cells, we further showed 154 
that HIV-1/HVEM entry of epithelial cells required the co-expression of all four glycoproteins 155 
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gB/gD/gH/gL (Fig. 3b). The control virus, HIV-1/BaL without HVEM incorporation, only 156 
infected CD4/CCR5- but not gB/gD/gH/gL-expressing cells. In contrast, HIV-1/HVEM, due to 157 
the lack of HIV-1 Env, infected gB/gD/gH/gL-expressing cells, but not those with CD4/CCR5 158 
expression (Fig. 3b). 159 
 160 
We further addressed the influence of gB/gD/gH/gL expression level on the entry efficiency of 161 
HIV-1/HVEM. Our results showed that the amount of in-cell HIV-1/HVEM increased along 162 
with the gB/gD/gH/gL expression level (data not shown). Moreover, blockade of gD by an 163 
antibody significantly inhibited the entry of HIV-1/HVEM into gB/gD/gH/gL-expressing 164 
epithelial cells, further reinforcing the significance of gD-HVEM interaction in this process (Fig. 165 
3c). 166 
 167 
PBMC-propagated HIV-1 infects HSV-2-infected human foreskin epithelial cells. 168 
The results above indicated that HVEM-bearing HIV-1, via an HVEM-gB/gD/gH/gL dependent 169 
manner, could successfully bind to and subsequently enter HSV-2-infected epithelial cells. To 170 
further confirm our findings in a physiologically relevant system, HIV-1BaL was propagated in 171 
PBMCs and its ability to infect HSV-2-infected primary foreskin epithelial cells was determined. 172 
In accordance with the findings above, our results showed that HIV-1, albeit at a very low level, 173 
could infect HSV-2-infected foreskin epithelial cells. Moreover, this infection could be 174 
substantially inhibited by neutralizing antibodies against HSV-2 gD or HVEM (Fig. 4).  175 
 176 
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Taken together, our data reveal that HIV-1 can obtain HVEM from the host cell membrane and 177 
such HVEM-bearing virus can infect HSV-2-infected non-HIV-1-target cells through an HVEM-178 
gB/gD/gH/gL dependent manner.  179 
 180 
DISCUSSION 181 
For an infection to occur, HIV-1 must cross the mucosal epithelial barrier [26]. HSV-2 infection-182 
resulted disruption of mucosal integrity has been proposed to be one of the mechanisms 183 
accounted for HSV-2-enhanced HIV-1 acquisition and transmission. However, the fact that 184 
enhanced HIV-1 infection can occur in HSV-2 asymptomatic stage suggests the existence of 185 
other mechanisms [27]. In the asymptomatic phase, HSV-2 replication and viral shedding still 186 
take place [28]. This persistent viral replication could result in phenotype changes to the infected 187 
epithelial cells other than ulceration, which might be in favor of the cross of mucosal epithelial 188 
barrier by HIV-1. In the current study, we revealed that HSV-2 replication results in the presence 189 
of viral glycoproteins on the infected cell surface, which can be targeted by HIV-1 through viral 190 
membrane-retained HVEM. HVEM interaction with HSV-2 gD in the presence of the other three 191 
viral glycoproteins gB/gH/gL can subsequently lead to HIV-1 infection of epithelial cells. Our 192 
findings reveal a potential new mechanism underlying HSV-2-enhanced HIV-1 mucosal 193 
transmission, which may facilitate HIV-1 to cross mucosal epithelia. 194 
 195 
HIV-1 co-infection with other viruses/pathogens is not uncommon. HIV-1 infection of CD4- 196 
keratinocytes has been described under the condition of co-infection with HSV-1[18], although 197 
the underlying mechanism remains to be fully defined. HSV-2 has a high genetic similarity to 198 
HSV-1, with about 83 % protein sequence identity. Moreover, these two viruses share almost 199 
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identical arrangement of open reading frames and can form various recombinant viruses in in 200 
vitro culture [29-31]. Given the high resemblance of these two viruses, it is likely that the 201 
incidence of HIV-1 infection of keratinocytes under HSV-1 co-infection may also take place 202 
under HSV-2 co-infection. Indeed, our study here revealed that HIV-1 infection of keratinocytes 203 
occurred under the condition of HSV-2 co-infection. Our results further showed that HIV-1 entry 204 
of non-target cell was mediated by HVEM on HIV-1 through interaction with gB/gD/gH/gL on 205 
HSV-2 infected epithelial cells. Furthermore, since HSV-1 adopts a similar entry mechanism as 206 
does HSV-2, such HVEM-gB/gD/gH/gL-mediated HIV-1 infection may provide an explanation 207 
for the phenomenon that HIV-1 can infect CD4- keratinocytes under the condition of HSV-1 co-208 
infection.  209 
 210 
HIV-1 infects CD4+ T cells, macrophages and dendritic cells, while CD4- keratinocytes are 211 
usually non-permissive to HIV-1. As mentioned above, in the case of co-infection with viruses 212 
like HSV-1, HTLV-1 and XMRV, HIV-1 infection of a range of non-target cells has been 213 
described, but the efficiency of these atypical infections has not been documented [18-20]. In the 214 
current study, we revealed that epithelial cells could be infected by HIV-1 providing that these 215 
cells are productively infected by HSV-2. Nevertheless, the proportion of HIV-1-infected 216 
epithelial cells was rather small. Of more than 90 % of HSV-2-infected primary foreskin 217 
epithelial cells, approximately 2 % of them were co-infected by HIV-1. Although the reasons for 218 
the low co-infection rate might be multifaceted, we believe that the cell condition at the time of 219 
HIV-1 infection is critical for the success of HIV-1 infection and replication. A successful HIV-1 220 
infection appeared to rely on early HSV-2 infection (4-6 h). When cells were infected for a 221 
longer period of time with HSV-2 (16-20 h), the binding of HIV-1 to cell surface increased, but 222 
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intracellular HIV-1 dropped to a level below detection limit, suggesting that there were more 223 
glycoproteins expressed on the cell surface but the cell condition might not be suitable for HIV-1 224 
replication (Fig.2a and unpublished data). Twenty hours post infection is the time close to the 225 
release of HSV-2 progeny viruses. At this time point, cellular resources might be exhausted by 226 
HSV-2 replication and cells overloaded with HSV-2 progeny virus particles are ready for 227 
extracellular transportation[32]. Therefore, the condition of the cells at this time point may not be 228 
ideal for HIV-1 entry and replication. We postulate that a successful HIV-1/HVEM infection of 229 
HSV-2-infected epithelial cells likely takes place only at the stage of HSV-2 early replication. At 230 
the early stage of HSV-2 infection (e.g. 4-6 h after infection), although the expression levels of 231 
HSV-2 glycoproteins are relatively low, gD expressed on the cell surface could mediate an 232 
interaction with HIV-1/HVEM and consequently result in a low level of HIV-1 infection. It is 233 
known that HIV-1 transmission often results from infection by a single transmitted/founder 234 
virus, indicating that a high quantity of infection may not be necessary for HIV-1 to establish a 235 
productive infection [33]. In our study, although HIV-1/HVEM-mediated infection of epithelial 236 
cells was low, we did observe a productive HIV-1 infection, revealing that the in-cell HIV-1 p24 237 
was inhibited by reverse transcriptase inhibitor AZT (Fig. 3a), which is in agreement with a 238 
previous study that HIV-1 can replicate in epithelial cells under the coinfection condition[20]. 239 
Therefore, although HVEM-gB/gD/gH/gL-mediated HIV-1 infection of primary epithelial cells 240 
is not efficient, such advantage that HIV-1 has acquired may significantly increase the chances 241 
of successful mucosal transmission.  242 
 243 
In addition to primary epithelial cells, we used two epithelial cell lines HeLa and ME-180 cells 244 
in the current study. A similar tendency of results, albeit with difference, was observed in the 245 
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two cell lines. A higher level of HIV-1/HVEM binding and entry was observed in ME-180 cells 246 
than in HeLa cells. In agreement, we observed that, following transfection with gD expressing 247 
constructs, ME-180 had higher level of HSV-2 gD on the cell surface than HeLa. Likewise, ME-248 
180 was more sensitive to HSV-2 infection compared to HeLa (Fig. S2 and S3). Unexpectedly, 249 
we found that HIV-1 infection of HSV-2-infected ME-180 was in a lower quantity than in HeLa 250 
cells (Fig. 3a). Although the mechanism remains to be further addressed, this was likely caused 251 
by the higher rate of cell death on ME-180 than on HeLa cells upon HSV-2 infection. In 252 
addition, we observed basal level of HIV-1 binding to both HeLa and ME-180 cells and this was 253 
independent of either HVEM expression or HSV-2 infection, suggesting that other interactions 254 
between proteins from viral and cell membranes may be involved. Indeed, a wide range of host 255 
proteins, including MHC restriction factors HLA-I and HLA-II, cell adhesion molecule vascular 256 
cell adhesion molecule 1 (VCAM-1), integrin lymphocyte function-associated antigen 1 (LFA-257 
1), T cell signaling molecules CD3 and CD4, have previously been shown to be detected on 258 
HIV-1 virions [34, 35]. HIV-1 infection of epithelial cells has also been described in in vitro and 259 
clinical studies in the absence of HSV-2 co-infection, indicating the potential involvement of 260 
unknown host factors during HIV-1 infection [36, 37]. Although beyond the scope of the current 261 
study, it will be interesting to explore the roles of other host proteins on HIV-1 virions in future 262 
studies.  263 
 264 
It is unclear why HVEM was not identified previously in HIV-1 virions. To identify virion-265 
associated host proteins, differences in methodology and cells used for virus production likely 266 
result in different outcomes. It is known that, using traditional methods like immunoblotting, 267 
only very limited number of host proteins were identified [21, 34]. Although the adoption of 268 
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proteomic analysis has substantially increased the number of proteins identified in HIV-1 virions, 269 
so far there have been only a few studies with different results. There is no guarantee to identify 270 
all host proteins in virions using the technique. Of note, membrane proteins, due to their 271 
heterogeneous hydrophobic nature, are in general under-represented in proteomic studies [38]. 272 
For instance, CD48 is highly expressed on immunocytes including T cells, but its detection in 273 
HIV-1 virions requires a second purification step by affinity chromatography in addition to 274 
conventional LC-MS/MS [39]. Another example is that, tetraspanin enriched membranes (TEMs) 275 
are components frequently reported in HIV-1 envelope but have not been reported to be present 276 
in HIV-1 virions in the previous proteomic study [35]. 277 
 278 
Taken together, our study reveal that HIV-1 can obtain HSV-2 receptor HVEM from host cells 279 
during budding and that HVEM interaction with HSV-2 glycoprotein D in the presence of the 280 
other three viral glycoproteins gB/gH/gL on HSV-2-infected cell surface can mediate HIV-1 281 
infection of non-target epithelial cells. Findings in this study provide a potential new mechanism 282 
underlying HSV-2 enhanced HIV-1 acquisition and transmission from a different perspective 283 
and may shed light on new treatment strategies against HIV-1/HSV-2 co-infection.   284 
  285 
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METHODS 286 
Cells, plasmids and viruses 287 
Human embryo kidney cell line HEK293T, African green monkey kidney cell line Vero and 288 
human cervical epithelial cell lines HeLa and ME-180 were purchased from the American Type 289 
Culture Collection. U87-CD4.CCR5 was obtained from the NIH AIDS Research and Reference 290 
Reagent Program, Division of AIDS, NIH. Primary PBMCs were isolated from peripheral blood 291 
of healthy donors using Ficoll-Hypaque density gradient (GE Healthcare) according to the 292 
manufacturer’s instructions and cultured in RPMI-1640 medium supplemented with 10 % fetal 293 
bovine serum (FBS) and antibiotics. For HIV-1 propagation in PBMCs, cells were pre-treated 294 
with 20 U/mL interluekin-2 (IL-2; R&D Systems) and 1 µg/mL phytohaemagglutinin (PHA; 295 
Sigma-Aldrich) for 7 days before HIV-1 inoculation. Foreskin samples were obtained from 296 
teenagers underwent circumcision from Jiangxi Provincial Maternal and Child Health Hospital. 297 
Foreskin epithelial cells were isolated using Dispase II (ThermoScientific) digestion as 298 
previously described and cultured in EpiLife medium (ThermoScientific) supplemented with 299 
EpiLife™ Defined Growth Supplement (ThermoScientific) and antibiotics [40].  300 
 301 
HIV-1 env-deficient luciferase reporter gene-containing backbone plasmid pNL4-3.Luc.R-E- and 302 
HIV-1 Env BaL-expressing construct were obtained from the NIH AIDS Research and 303 
Reference Reagent Program, Division of AIDS, NIH.  pcDNA3.1(+) was purchased from Life 304 
Technology, ThermoScientific. Human HVEM, CD4 and CCR5 were cloned from human cDNA 305 
library. The open reading frames (ORFs) of HSV-2 glycoproteins gB, gD, gH and gL were 306 
amplified from HSV-2 genome. All these genes were inserted into pcDNA3.1(+) vector.  307 
 308 
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HSV-2 (G strain; LGC standards) was propagated in HeLa cells and titrated in Vero cells as 309 
previously described [41].  For the production of pseudoviruses HIV-1/HVEM and HIV-1/BaL, 310 
HIV-1 backbone plasmid pNL4-3.Luc.R-E- with either HVEM or BaL expression construct were 311 
co-transfected at a ratio of 3:2 into 293T cells using Lipofectamine 2000 (ThermoScientific) 312 
according to the manufacturer’s instructions. Forty-eight hours post transfection, culture 313 
supernatants were collected and filtrated through 0.45 µm filters to remove cell debris.  Filtered 314 
viruses were mixed with FBS to reach a final concentration of 20% and aliquoted and stored at -315 
80 °C till use.  Infectious clone to generate replication-competent virus HIV-1BaL was obtained 316 
from the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIH and 317 
viruses were produced by transfection of 293T cells using Lipofectamine 2000. To generate 318 
PBMC-derived HIV-1BaL, viruses produced from 293T cells were used to infect PBMCs. Three 319 
to four days post infection, culture supernatants were filtered, mixed with FBS, aliquoted and 320 
stored at -80 °C till use.  All HIV-1 viruses were titrated by p24 ELISA.  321 
 322 
HVEM cell surface expression 323 
The expression of HVEM on CD4+ PBMCs was analyzed by flow cytometry. Freshly isolated 324 
PBMCs were stained with PE-conjugated anti-HVEM antibody (Biolegend) and FITC-325 
conjugated anti-CD4 (BD Biosciences) for 30 min at 4 °C. After washes, cells were evaluated on 326 
a BD LSRFortessa platform. 327 
 328 
Virus concentration and purification 329 
Ultracentrifugation was used for concentration of HIV-1 particles as previously described with 330 
modifications [42].  In brief, virus stocks were laid onto a 10 % iodixanol cushion and 331 
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centrifuged at 50,000 g for 1.5 h at 4 °C using a Beckman SW32 Ti swinging-bucket rotor 332 
(Beckman Coulter).  The pelleted viruses were suspended with 1 mL PBS, aliquoted and stored 333 
at -80 °C till use. 334 
 335 
Virus purification was performed using 6–18% Optiprep™ density gradient as previously 336 
described with modifications [43]. In brief, concentrated viruses in PBS were layered on the top 337 
of a 6–18% Optiprep™ density gradient and centrifuged at 200,000 g for 1.5 h at 4 °C using a 338 
Beckman SW41 Ti swinging-bucket rotor (Beckman Coulter). After centrifugation, gradients 339 
were collected in 1 mL fractions by upward displacement and the purified viruses were sharply 340 
in the bottom of the third of the gradients. 341 
 342 
Western blot 343 
Ultracentrifugation concentrated or density gradient purified viruses were lysed with 1 % Triton 344 
X-100 for 1 h in a 37 °C water bath and then mixed with SDS-PAGE loading buffer and boiled 345 
for 10 min. Thereafter, samples were separated by 10 % SDS-PAGE and transferred onto a 346 
PVDF membrane. Membrane was blocked with 5 % non-fat milk and incubated sequentially 347 
with primary antibodies and HRP-conjugated goat anti-mouse IgG (Santa Cruz) overnight at 4 348 
°C and for 1 h at room temperature, respectively. Following incubations, the membrane was 349 
extensively washed and immunobands were visualized with ECL substrates (Millipore) under a 350 
CCD camera (Fujifilm LAS4000). The following primary antibodies were used in the current 351 
study for Western blot: mouse anti-human HVEM (R&D systems), mouse anti-human AChE 352 
(Millipore) and mouse anti-HIV-1 p24 Gag monoclonal (NIH AIDS Reagent Program, Division 353 
of AIDS, NIAID, NIH) [44].  354 
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 355 
Preparation of anti-gB/gD murine antibody 356 
Murine anti-gB or -gD sera were prepared as previously described [42, 45]. In brief, 6-8 week 357 
old BALB/c mice were immunized intramuscularly with 20 µg of plasmids expressing HSV-2 358 
gB or gD into the quadriceps of both legs, followed by in vivo electroporation using the ECM830 359 
Square Wave Electroporation System (BTX). Immunization was repeated for three times at 3-360 
week intervals. One week after the final immunization, mice were sacrificed and sera were 361 
collected and purified with protein A/G (ThermoScientific). The purified anti-gB or -gD sera 362 
were designated as mouse anti-gB and anti-gD antibodies, respectively.  363 
 364 
gB/gD cell surface expression 365 
The expression of gB and gD on HSV-2-infected cell surface was determined by cell-based 366 
ELISA (CELISA) and flow cytometry as previously described [46]. In brief, HeLa cells were 367 
infected with HSV-2 at an MOI of 0.1 or 1 for up to 28 h (CELISA) or 24 h (flow cytometry) 368 
before the expression of gB and gD on cell surface was determined.  369 
For CELISA, cells were fixed with 4 % paraformaldehyde for 15 min, rinsed with PBS and 370 
incubated sequentially with mouse anti-gB or -gD antibodies and HRP-conjugated goat anti-371 
mouse IgG both for 1 h at room temperature. After extensive washes, TMB solution was added 372 
for colorimetric reaction followed by the addition of stop solution (2N H2SO4).  OD values were 373 
read by an ELISA plate reader (Tecan) at a test wavelength of 450 nm and a reference 374 
wavelength of 570 nm. 375 
For flow cytometry, cells were collected and washed with PBS and incubated with mouse anti-376 
gB or -gD antibodies and FITC-conjugated goat anti-mouse IgG both for 30 min at 4 °C. After 377 
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washes, cells were suspended in 1 % paraformaldehyde fixation solution and evaluated on a BD 378 
LSRFortessa platform. 379 
 380 
Cell survival assay 381 
HeLa cells were infected with HSV-2 at an MOI of 0.1 or 1 for up to 36 h, and cells were 382 
subsequently collected and incubated with 7-amino-actinomycin D (7-AAD, Biolegend) for 10 383 
min in the dark, followed by immediate evaluation by flow cytometry on a BD LSRFortessa 384 
platform. 385 
 386 
Virus binding assay 387 
HeLa or ME-180 cells were infected with HSV-2 (1 MOI) for 4 or 16 h, or transfected with a 388 
combination of HSV-2 gB, gD, gH and gL plasmids for 24 h, followed by an incubation with 389 
200 ng HIV-1/HVEM for 1 h at 4 °C. Cells were then extensively washed with PBS to remove 390 
unbound viruses. To measure cell bound viruses, washed cells were lysed with 1 % Triton X-100 391 
and HIV-1 p24 was quantified by ELISA as previously described [47, 48].  392 
 393 
Virus entry assay 394 
HeLa or ME-180 cells were either infected with HSV-2 (1 MOI) for 4-6 h or transfected with a 395 
combination of HSV-2 gB, gD, gH and gL plasmids for 24 h, and then infected with 200 ng of 396 
replication-competent HIV-1BaL/HVEM (for HSV-2 infection) or pseudotyped HIV-1/HVEM 397 
(for HSV-2 glycoprotein transfection) for 2 h. For AZT (NIH AIDS Research and Reference 398 
Reagent Program, Division of AIDS, NIH) treatment, AZT at the final concentration of 10 µM 399 
was added 1 h before HIV-1 infection and remained throughout the assay [20]. Thereafter, cells 400 
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were washed with PBS to remove unbound virus and cultured in complete medium for another 401 
24 h. Cells were trypsinized to remove cell surface associated viruses followed by washes and 402 
lysis [49]. The treatment with trypsin was to ensure that only in-cell p24 was measured in the 403 
following experiments. HIV-1 p24 (for HSV-2 infection) or luciferase activity (for HSV-2 404 
glycoprotein transfection) was measured. HIV-1/BaL infection of CD4/CCR5 transfected cells 405 
was used as control. For HSV-2 glycoprotein concentration assay, cells were transfected with 406 
ascendant doses of gB, gD, gH and gL. For gD blocking assay, cells transfected with gB, gD, gH 407 
and gL were treated with mouse anti-gD antibody or control IgG for 1 h at 37 °C before used for 408 
HIV-1/HVEM infection.  409 
 410 
Infection of foreskin epithelial cells 411 
Foreskin epithelial cells were first infected with HSV-2 (1 MOI) for 4-6 h, followed by infection 412 
with PBMC-propagated replication-competent HIV-1BaL (200 ng) for 2 h. Cells were 413 
subsequently washed with PBS to remove unbound virus and cultured in complete medium for 414 
another 24-30 h. For antibody blocking, anti-gD or anti-HVEM antibodies were used to treat 415 
epithelial cells or HIV-1BaL for 1 h at 37 °C prior to co-infection. After infection, cells were 416 
trypsinized to remove cell surface viruses, washed and stained with mouse anti-gD antibody 417 
followed by FITC-conjugated goat anti-mouse IgG, both for 30 min at 4 °C. After washes, cells 418 
were fixed, permeabilized and stained with PE-conjugated anti-HIV-1 p24 (Beckman Coulter) 419 
for another 30 min at 4 °C. Cells were then washed and evaluated by flow cytometry on a BD 420 
LSRFortessa platform. 421 
 422 
Statistical analysis 423 
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All data were expressed as mean ± standard deviation (SD) and analyzed by GraphPad Prism 424 
7.02. Mann-Whitney test was used for comparisons between two groups while Kruskal-Wallis 425 
test was used for comparisons among three or more groups. A p value less than 0.05 was 426 
considered statistically significant.   427 
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Figure Legends 576 
Figure 1. Presence of HVEM on HIV-1 virions. (a) HVEM expression on freshly isolated 577 
PBMCs. Freshly isolated PBMCs were stained with PE-conjugated anti-HVEM and FITC-578 
conjugated anti-CD4 antibodies. The expression of HVEM and CD4 on PBMCs were analyzed 579 
by flow cytometry. (b) 293T, 293T-HVEM and PBMC-derived HIV-1 virus stocks, and mock-580 
treated cell supernatants were pelleted by ultracentrifugation and HVEM, AChE and HIV-1 p24 581 
in the pellets were determined by Western blot. One representative experiment out of three is 582 
shown. (c) Concentrated 293T, 293T-HVEM and PBMC-derived HIV-1 virus stocks were 583 
purified by 6–18% Optiprep™ density gradient, and HVEM, AChE and HIV-1 p24 in the 584 
purified viruses were determined by Western blot. One representative experiment out of three is 585 
shown. 586 
 587 
Figure 2. Binding of HIV-1/HVEM to HSV-2-infected cell surface through HVEM-gD 588 
interaction. (a) HeLa or ME-180 cells were mock infected or infected with 1 MOI of HSV-2 for 589 
4 or 16 h and then incubated with 200 ng HIV-1/HVEM or HIV-1/BaL for 1 h at 4 °C. 590 
Following incubation, cell-bound HIV-1 p24 was quantified. Data shown are mean ± SD of three 591 
independent experiments. (b) HeLa or ME-180 cells were transfected with pcDNA3.1 or 592 
plasmids expressing HSV-2 gB/gD/gH/gL for 24 h and then incubated with 200 ng HIV-593 
1/HVEM for 1 h. Following incubation, cell-bound HIV-1 p24 was quantified. Data shown are 594 
mean ± SD of three independent experiments. *, p < 0.05; **, p <0.01. 595 
 596 
Figure 3. Entry of HIV-1/HVEM into HSV-2-infected cells through HVEM-gB/gD/gH/gL-597 
dependent manner. (a) HeLa or ME-180 cells were infected with 1 MOI of HSV-2 for 4-6 h and 598 
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then incubated with 200 ng HIV-1BaL/HVEM for another 24 h in the presence or absence of 599 
AZT. Following incubation, cell surface viruses were removed by trypsin treatment and in-cell 600 
p24 was quantified. Data shown are mean ± SD of three independent experiments. (b-c) HeLa or 601 
ME-180 cells were transfected with plasmids expressing HSV-2 gB/gD/gH/gL or CD4/CCR5 for 602 
24 h, and then untreated (b) or treated with anti-gD antibody or control Ig (c), followed by 603 
infection with HIV-1/HVEM or HIV-1/BaL for another 24 h. In-cell luciferase activity was 604 
measured. Data shown are mean ± SD of three independent experiments. ns, not statistically 605 
significant; *, p < 0.05; **, p <0.01. 606 
 607 
Figure 4. PBMC-propagated HIV-1BaL infection of HSV-2-infected primary foreskin epithelial 608 
cells. Foreskin epithelial cells were infected with HSV-2 for 4-6 h and then incubated with HIV-609 
1 for another 24-30 h in the presence or absence of inhibitory antibodies. Following infection, 610 
cell surface viruses were removed by trypsin treatment. gD and in-cell p24 were stained and 611 
analyzed by flow cytometry. One representative experiment out of three is shown. 612 
 613 
Figure 1 Click here to download Figure Fig1.tif 
Figure 2 Click here to download Figure Fig2.tif 
Figure 3 Click here to download Figure Fig3.tif 
Figure 4 Click here to download Figure Fig4.tif 
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Supplemental Materials 
Figure S1: Expression of viral glycoproteins on HSV-2-infected cell surface. (a-b) 
HeLa cells were infected with 0.1 or 1 MOI of HSV-2 for an ascending time periods 
and then cell surface expression of gB (a) and gD (b) was measured by CELISA. Data 
shown are mean ± SD of three independent experiments. (c) HeLa cells were infected 
with 0.5 or 1 MOI of HSV-2 for 24 h and then cell surface expression of gB and gD 
was measured by flow cytometry. One representative experiment out of three is 
shown. 
 
  
Supplementary Material Files Click here to download Supplementary Material Files
Supplemental materials.pdf
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Figure S2: Impact of HSV-2 infection on cell viability. HeLa and ME-180 cells were 
mock-infected or infected with HSV-2 (MOI 0.1-1) for 30 h and then cell morphology 
was observed under microscope while cell viability was determined by 7-AAD 
staining. One representative experiment out of two is shown.  
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Figure S3: Viral glycoprotein expression on transiently transfected HeLa and 
ME-180 cells. HeLa and ME-180 cells were cotransfected with plasmids expressing 
HSV-2 gB, gD, gH and gL for 24 h and then cell surface gD was determined by flow 
cytometry. One representative experiment out of two is shown. 
 
